Combined transplantation of autologous hematopoietic stem cells and allogenic mesenchymal stem cells increases T regulatory cells in systemic lupus erythematosus with refractory lupus nephritis and leukopenia

Lupus

Volumn 24, Issue 11, 2015, Pages 1221-1226

  Wang, Q ^a   Qian, S ^a   Li, J ^a   Che, N ^a   Gu, L ^a   Liu, Y ^a   Mei, H ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Hematopoietic stem cell transplant; mesenchymal stem cells; systemic lupus erythematosus; Treg cells

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; LEFLUNOMIDE; MYCOPHENOLATE MOFETIL; THYMOCYTE ANTIBODY;

ADAPTIVE IMMUNITY; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LABORATORY TEST; LEUKAPHERESIS; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEINURIA; REGULATORY T LYMPHOCYTE; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; ADVERSE EFFECTS; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MESENCHYMAL STEM CELL TRANSPLANTATION; MONONUCLEAR CELL; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES;

ADULT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTES, MONONUCLEAR; LEUKOPENIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MESENCHYMAL STEM CELL TRANSPLANTATION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84941213457     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315583541     Document Type: Article

References (23)

1. Rahman A, Isenberg DA,. Systemic lupus erythematosus. N Engl J Med 2008; 358: 929-939.
2. Lipsky PE,. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
3. Shlomchik MJ, Craft JE, Mamula MJ,. From T to B and back again: Positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001; 1: 147-153.
4. Burt RK, Traynor A, Statkute L,. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 527-535.
5. Smith-Berdan S, Gille D, Weissman IL,. Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of puriï¬ ed allogeneic hematopoietic stem cells. Blood 2007; 110: 1370-1378.
6. Loh Y, Oyama Y, Statkute L,. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 2007; 109: 2643-2648.
7. Friedenstein AJ, Chailakhyan RK, Latsinik NV,. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues.Cloning in vitro and retransplantation in vivo. Transplantation 1974; 17: 331-340.
8. Owen M, Friedenstein AJ,. Stromal stem cells: Marrow-derived osteogenic precursors. Ciba Found Symp 1998; 136: 42-60.
9. Nauta AJ, Fibbe WE,. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
10. Sotiropoulou PA, Perez SA, Gritzapis AD,. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
11. Chen X, Armstrong MA, Li G,. Mesenchymal stem cells in immunoregulation. Immunol Cell Biol 2006; 84: 413-421.
12. Burt RK, Traynor AE, Pope R,. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505-3514.
13. Sanna G, Bertolaccini ML, Mathieu A,. Central nervous system lupus: A clinical approach to therapy. Lupus 2003; 12: 935-942.
14. Traynor AE, Barr WG, Rosa RM,. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arth Rheum 2002; 46: 2917-2923.
15. Burt RK, Marmont A, Schroeder J,. Intense immune suppression for systemic lupus-the role of hematopoietic stem cells. J Clin Immunol 2000; 20: 31-37.
16. Alchi B, Jayne D, Labopin M,. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: Data from the European Group for Blood and Marrow Transplantation registry. Lupus 2013; 22: 245-253.
17. Euler HH, Marmont AM, Bacigalupo A,. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996; 88: 3621-3625.
18. Tse WT, Pendleton JD, Beyer WM,. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003; 75: 389-397.
19. Maccario R, Podesta M, Moretta A,. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516-525.
20. La Cava A,. T-regulatory cells in systemic lupus erythematosus. Lupus 2008; 17: 421-425.
21. Wang D, Li J, Zhang Y,. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: A multicenter clinical study. Arth Res Ther 2014; 25; 16 (2): R79-R79.
22. Wang D, Feng X, Lu L,. A CD8 T cell/indoleamine 2,3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arth Rheum 2014; 66: 2234-2245.
23. Liu RH, Li YQ, Zhou WJ,. Supplementing mesenchymal stem cells improves the therapeutic effect of hematopoietic stem cell transplantation in the treatment of murine systemic lupus erythematosus. Transplant Proc 2014; 46: 1621-1627.